The rapidly expanding networks of psychedelics-based treatment clinics is a horse race where EVERYONE is a winner.

MINDCURE announces its Q1 fiscal 2022 results, including initial release of its iSTRYM platform. Cash and equivalents of CAD$15.6 million as of August 31, 2021.

Cybin receives IND authorization from the FDA to study ketamine’s psychedelic effect on the cerebral cortex.

MindMed announces a new R&D initiative focused on an MDMA derivative, and aimed at treating social anxiety.

Washington, D.C. voters are strongly in favor of proposals to broadly decriminalize drugs and establish harm reduction centers, a new poll found.

Psychedelic drugs are all over the news. Not just general news but also business media. Big news. Big Business.

Levitee Labs announces new credit facility for up to CAD$12 million to finance expansion of its clinics network.

Levitee Labs announces a partnership with Adracare Inc., a subsidiary of Well Health Technologies (WELL), to build out a digital therapeutics platform.

Costa Rica’s Congress on Tuesday voted to legalize cannabis for medical use despite opposition from President Carlos Alvarado, Reuters reports. Independent lawmaker Zoila Volio told Reuters that she trusts Alvarado understands the reforms will not increase cannabis use in the nation and will not veto the law.

A fourth Massachusetts city has enacted a psychedelics policy change, with members of the Easthampton City Council voting on Wednesday in favor of a resolution urging the decriminalization of certain entheogenic substances and other drugs.